Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03614637 · ClinicalTrials.gov registry record
Cannabis Use and Epigenetic Alterations in Human Male Sperm Cells
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 42
- Enrollment target
NCT03614637: Completed study, sponsored by Duke University.
NCT03614637 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03614637 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
This is a follow-up project to a proof-of-concept study to determine if Cannabis use in male humans is associated with changes in deoxyribonucleic acid (DNA) methylation profile of sperm. This proposal will examine the epigenome of sperm from men actively using Cannabis before and after a period of Cannabis abstinence. The results will be compared to control non-users.
Primary Outcome
We will compare the overall DNA methylation profiles in sperm cells of user and non-user group to replicate findings in the pilot study.
Interventions
- OTHER Cannabis use abstinence for 11 weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-11-07 |
| Est. Completion | 2020-03-16 |
What the finished NCT03614637 record still lists
NCT03614637 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Cannabis use abstinence for 11 weeks is the first listed.
NCT03614637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03614637 about?
NCT03614637 is a clinical study titled "Cannabis Use and Epigenetic Alterations in Human Male Sperm Cells". This is a follow-up project to a proof-of-concept study to determine if Cannabis use in male humans is associated with changes in deoxyribonucleic acid (DNA) methylation profile of sperm. This proposal will examine the epigenome of sperm from men actively using Cannabis before and after a period of ...
What is the current status of trial NCT03614637?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2017-11-07. Estimated completion is 2020-03-16.
What interventions are being tested in trial NCT03614637?
The interventions under investigation include: Cannabis use abstinence for 11 weeks (OTHER).
Who is sponsoring clinical trial NCT03614637?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI